Efficacy and Safety of BGG492 in the Treatment of Migraine
NCT ID: NCT00892203
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
75 participants
INTERVENTIONAL
2009-04-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
NCT01617941
Study in Participants With Acute Migraines Headaches
NCT00804973
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
NCT00095004
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
NCT00888680
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
NCT00897104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
BGG492
Comparator
Sumatriptan
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BGG492
Sumatriptan
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 migraine episode, but not more 15 migraine days per month
* Past use of triptans
* Migraine onset before 50 years of age
Exclusion Criteria
* More than 6 non-migraine headaches per month
* Patients receiving migraine prophylaxis treatment
* Patients receiving regular treatment with psychoactive drugs
* Smokers
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Investigator Site
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140
Glendale, California, United States
California Clinical Trials, 15625 Lakewood Boulevard
Paramount, California, United States
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Göttingen, , Germany
Novartis Investigator Site
Hamburg, , Germany
Novartis Investigative Site
Kiel, , Germany
Novartis Investigative Site
Königstein, , Germany
Novartis Investigative Site
Munich, , Germany
Novartis Investigator Site
Munich, , Germany
Novartis Investigative Site
Münster, , Germany
Novartis Investigative Site
Würzburg, , Germany
Novartis Investigative Site
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CBGG492A2204 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005392-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CBGG492A2204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.